Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.74B P/E - EPS this Y 107.40% Ern Qtrly Grth -
Income -263.3M Forward P/E 304.14 EPS next Y 1,100.00% 50D Avg Chg -6.00%
Sales 753.2M PEG -130.49 EPS past 5Y -37.87% 200D Avg Chg 4.00%
Dividend N/A Price/Book 2.08 EPS next 5Y -8.20% 52W High Chg -24.00%
Recommedations 2.70 Quick Ratio 1.64 Shares Outstanding 89.87M 52W Low Chg 53.00%
Insider Own 2.40% ROA -7.40% Shares Float 74.59M Beta 1.96
Inst Own 103.06% ROE -31.55% Shares Shorted/Prior 4.80M/3.70M Price 21.29
Gross Margin 68.64% Profit Margin -34.96% Avg. Volume 519,954 Target Price 24.36
Oper. Margin -12.56% Earnings Date May 1 Volume 294,898 Change -2.20%
About Myriad Genetics, Inc.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Myriad Genetics, Inc. News
03/28/24 Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?
03/27/24 Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay
03/21/24 Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
03/20/24 Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
03/01/24 Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact
09:50 AM Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
05:48 AM Myriad Genetics Full Year 2023 Earnings: EPS Misses Expectations
02/28/24 Q4 2023 Myriad Genetics Inc Earnings Call
02/28/24 Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript
02/28/24 Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down
02/27/24 Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say
02/27/24 Myriad Genetics (MYGN) Tops Q4 Earnings and Revenue Estimates
02/27/24 Myriad Genetics Inc (MYGN) Reports 11% Revenue Growth in Q4 and Full-Year 2023
02/27/24 Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
02/27/24 Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
02/26/24 Wall Street's Insights Into Key Metrics Ahead of Myriad (MYGN) Q4 Earnings
02/21/24 Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
02/16/24 Larry Robbins' Glenview Capital Management Bolsters Stake in Myriad Genetics Inc
02/15/24 Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
02/01/24 Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
MYGN Chatroom

User Image Stock_Titan Posted - 1 week ago

$MYGN Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date https://www.stocktitan.net/news/MYGN/myriad-genetics-announces-foundational-patent-granted-for-molecular-adw01d9iu14i.html

User Image DonCorleone77 Posted - 1 week ago

$MYGN Myriad Genetics announces patent granted for SneakPeek Snap device Myriad Genetics announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination.U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad's SneakPeek Snap products in the U.S through 2040. The patent further covers technology for improving the accuracy of a fetal sex test by reducing contaminating DNA in maternal blood samples. SneakPeek's blood collection innovation makes obtaining a blood sample at home quick and easy. Consumers place the Snap device on their arm, press the button, and the sample is collected in one to four minutes. Moreover, clinical studies have shown that the Snap device significantly reduces the risk of external male DNA contamination in maternal blood samples, ensuring high accuracy in fetal sex testing....

User Image Stock_Titan Posted - 1 week ago

$MYGN Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device https://www.stocktitan.net/news/MYGN/myriad-genetics-announces-patent-granted-for-sneak-peek-r-snap-h8r8l80z4ds5.html

User Image ca_rott1487 Posted - 1 week ago

$MYGN Agreed to settle $77.5M over allegations of misleading investors about their GeneSight test and financial situation. Even though the claim deadline has passed, it is still possible to file late claims https://11thestate.com/cases/myriad-genetics-settlement

User Image satsandstocks Posted - 3 weeks ago

$MYGN nice consolidation on daily - can be interesting when it breaks 23.75 -- which can potentially then push to 27.88

User Image ca_rott1487 Posted - 1 month ago

#MyriadGenetics $MYGN settling $77.5M over the GeneSight scandal and investors can still file for compensation. @MyriadGenetics #MYGN case page: https://11thestate.com/cases/myriad-genetics-settlement "The Complaint alleges Defendants made false/misleading statements about the Company's operations. Specifically, Defendants didn't disclose: (i) lack of evidence for GeneSight tests; (ii) FDA-requested changes and doubts about test benefits; (iii) ongoing FDA discussions; (iv) risks from acquiring Counsyl and Foresight; (v) resulting in materially false public statements."

User Image ca_rott1487 Posted - 1 month ago

#MyriadGenetics $MYGN settling $77.5M over the GeneSight scandal and investors can still file for compensation. #MYGN case page: https://11thestate.com/cases/myriad-genetics-settlement "The Complaint alleges Defendants made false/misleading statements about the Company's operations. Specifically, Defendants didn't disclose: (i) lack of evidence for GeneSight tests; (ii) FDA-requested changes and doubts about test benefits; (iii) ongoing FDA discussions; (iv) risks from acquiring Counsyl and Foresight; (v) resulting in materially false public statements."

User Image epsguid Posted - 1 month ago

$MYGN reported earnings of $0.04, consensus was ($0.06) via @eWhispers #epsbeat http://eps.sh/d/mygn

User Image Stock_Titan Posted - 1 month ago

$MYGN Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance https://www.stocktitan.net/news/MYGN/myriad-genetics-reports-strong-fourth-quarter-and-full-year-2023-8egjx360cr82.html

User Image Stock_Titan Posted - 1 month ago

$MYGN Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 https://www.stocktitan.net/news/MYGN/myriad-genetics-and-national-cancer-center-hospital-east-in-japan-6biex9wkwvsx.html

User Image Stock_Titan Posted - 1 month ago

$MYGN Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 https://www.stocktitan.net/news/MYGN/myriad-genetics-to-release-fourth-quarter-and-full-year-2023-00yadbct0s50.html

User Image Aigner_Andreas Posted - 2 months ago

#GoldenCross $MYGN at 22.22 R13 HiLo 84% T1Y 24 hold DIV N/A #Myriad Gen #stocks #trading #finance #market

User Image cctranscripts Posted - 2 months ago

Statement of acquisition of beneficial ownership by individuals https://www.conferencecalltranscripts.org/summary/?id=12891418 $MYGN

User Image tickeron Posted - 2 months ago

Good move or bad move? $MYGN RSI Indicator left the overbought zone. View odds of downtrend. https://srnk.us/go/4977736

User Image cctranscripts Posted - 2 months ago

Israel A. Englander just provided an update on share ownership of Myriad Genetics https://www.conferencecalltranscripts.org/summary/?id=12888262 $MYGN

User Image cctranscripts Posted - 2 months ago

BlackRock, Inc. just provided an update on share ownership of Myriad Genetics https://www.conferencecalltranscripts.org/summary/?id=12883799 $MYGN

User Image macroaxis Posted - 2 months ago

Myriad Genetics ( $MYGN ) buy or sell recommendation is STRONG BUY https://www.macroaxis.com/stock/MYGN/Myriad-Genetics #trading #ideas #stocks

User Image STCKPRO Posted - 2 months ago

$MYGN NEW ARTICLE : Myriad Genetics to acquire certain assets from Intermountain Precision Genomics https://stck.pro/news/MYGN/73140159/

User Image StockAutomatePro Posted - 2 months ago

$MYGN Chart analysis confirms an upward trend for the stock. We alerted the BUY signal at $18.21 and we were able to close this one with profit at $20.21🤙

User Image STCKPRO Posted - 2 months ago

$MYGN NEW ARTICLE : Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics https://stck.pro/news/MYGN/73104783/

User Image DonCorleone77 Posted - 2 months ago

$MYGN Myriad Genetics signs agreement to acquire certain assets from Intermountain Myriad Genetics announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics', or IPG, laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed. The acquisition is expected to close on February 1, 2024, subject to customary closing conditions. By bringing the Precise Tumor and Precise Liquid tests in house, Myriad will open up new opportunities for innovation, growth, and continued development of its oncology portfolio. The financial terms of the deal were not disclosed but are not material to either Myriad or Intermountain Healthcare.

User Image TrendyChart Posted - 2 months ago

$MYGN Technical intricacies on the stock chart unfold like a captivating story, where the plot revolves around a steadfast trend and weakening resistance. 🚀 https://trendychart.lpages.co/options/

User Image tickeron Posted - 2 months ago

How does this make you feel? $MYGN MACD Histogram turned positive on January 16, 2024. View odds of downtrend. https://srnk.us/go/4971292

User Image StockAutomatePro Posted - 2 months ago

$MYGN Chart analysis confirms a potential uptrend for the stock. We alerted the BUY signal at $18.15 and we were able to close this one with profit at $20.5725 🥳

User Image Last10K Posted - 2 months ago

$MYGN just filed with the SEC a Earnings Release and a Financial Exhibit https://last10k.com/sec-filings/MYGN/0000899923-24-000005.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=MYGN

User Image EarningsInsider Posted - 2 months ago

$MYGN updates FY23 guidance to ($0.33)-($0.28) EPS and revenue guidance to $747-$753 million. www.marketbeat.com/stocks/NASDAQ/MYGN/earning

User Image cctranscripts Posted - 2 months ago

©2024 Myriad Genetics, Inc. 42Nd Annual J.P. Morgan Healthcare Conference J A N U A R Y 1 0 , 2 https://www.conferencecalltranscripts.org/summary/?id=12868323 $MYGN

User Image risenhoover Posted - 2 months ago

$MYGN / Myriad Genetics files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 MYRIAD GENETICS, https://fintel.io/doc/sec-myriad-genetics-inc-899923-8k-2024-january-16-19738-5664?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image fin_researcher Posted - 2 months ago

$MYGN only one day left before deadline

User Image TrendyChart Posted - 2 months ago

$MYGN Bedrock support ensures enduring stability. 🏰 https://trendspider.com/?_go=options

Analyst Ratings
Goldman Sachs Buy Jan 30, 24
Goldman Sachs Buy Jan 29, 24
Piper Sandler Neutral Dec 21, 23
Wells Fargo Equal-Weight Dec 19, 23
Guggenheim Buy Dec 14, 23
Wolfe Research Outperform Dec 13, 23
JP Morgan Underweight Nov 7, 23
JP Morgan Underweight Aug 7, 23
Goldman Sachs Buy Jul 24, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Riggsbee Richard Bryan Chief Financial Offi.. Chief Financial Officer Nov 01 Sell 15.6874 30,000 470,622 321,812 11/03/23
SPIEGELMAN DANIEL K Director Director Jun 01 Sell 23.01 8,638 198,760 40,493 06/02/23
Lambert Nicole Chief Operating Offi.. Chief Operating Officer Mar 27 Sell 23.48 6,433 151,047 240,506 03/28/23
Lambert Nicole Chief Operating Offi.. Chief Operating Officer Mar 02 Sell 22.7414 13,184 299,823 215,220 03/03/23
Riggsbee Richard Bryan Chief Financial Offi.. Chief Financial Officer Jan 18 Sell 20.01 600 12,006 373,507 01/19/23
SPIEGELMAN DANIEL K Director Director Jun 06 Sell 19.2517 6,424 123,673 33,980 06/06/22
Hart Jayne B. Chief People Officer Chief People Officer Feb 28 Option 23.98 10,500 251,790 169,378 03/01/22
Hart Jayne B. Chief People Officer Chief People Officer Feb 28 Sell 25 10,500 262,500 165,878 03/01/22
LANCHBURY JERRY S Chief Scientific Off.. Chief Scientific Officer Aug 25 Option 27.07 80,000 2,165,600 262,550 08/25/21
LANCHBURY JERRY S Chief Scientific Off.. Chief Scientific Officer Aug 25 Sell 35.4 80,000 2,832,000 232,550 08/25/21
Phanstiel S. Louise Director Director Aug 06 Option 23.34 60,000 1,400,400 91,646 08/06/21
LANCHBURY JERRY S Chief Scientific Off.. Chief Scientific Officer Jul 08 Option 26.49 32,308 855,839 234,434 07/08/21
LANCHBURY JERRY S Chief Scientific Off.. Chief Scientific Officer Jun 28 Option 19.47 50,000 973,500 294,562 06/28/21
LANCHBURY JERRY S Chief Scientific Off.. Chief Scientific Officer Jun 28 Sell 32.02 83,372 2,669,571 232,550 06/28/21
LANCHBURY JERRY S Chief Scientific Off.. Chief Scientific Officer May 05 Option 19.47 19,360 376,939 285,282 05/05/21
LANCHBURY JERRY S Chief Scientific Off.. Chief Scientific Officer May 05 Sell 31.97 19,360 618,939 265,922 05/05/21
Lambert Nicole See Remarks See Remarks Apr 20 Sell 27.01 6,649 179,589 129,119 04/20/21
Hart Jayne B. Chief People Officer Chief People Officer Mar 30 Option 23.08 58,000 1,338,640 88,162 03/30/21
Hart Jayne B. Chief People Officer Chief People Officer Mar 30 Sell 30 58,000 1,740,000 80,128 03/30/21